FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
44.0 pts (24h)ChinaOne-OffHealth & Medicine4mo
KalshiCheck availabilityKYC required2% feeVerified resolution dataFairly calibratedCurrent implied probability
Yes 93%+44.0pt
Market quality
49 / 100
Low quality24h Volume
$780.4
Liquidity
$2.1K
Low liquidityBid / Ask
62.0% / 70.0%
Spread
8.0 pt
Wide spreadMarket data
Updated 17 minutes ago
Jun 17, 26, 9:00 PMJan 1, 27, 4:59 AM
Trends
Rules
If the FDA's decision on Ivonescimab by Summit Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
Settles via:AppliedXL
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
- Ivonescimab (also called AK112 or SMT112) is a bispecific antibody — think of it as a single engineered drug molecule that carries two different "hooks" instead of one, allowing it to grab and block two disease-promoting proteins at the same time.
- It was developed by Akeso and is being commercialized outside China by Summit Therapeutics.
- By simultaneously neutralizing both targets, ivonescimab is designed to slow cancer growth more effectively than drugs that block only one pathway at a time.
- This market and these products have not been endorsed by any aforementioned brands or its affiliates.
Open markets
China
POLYMARKETBest Chinese AI Company end of September?
- Alibaba+20.0pt77%
- Moonshot-15.7pt13%
- Z.ai-7.0pt6%
+8 more outcomes
- Total Vol
- $185.5K
- 24h Vol
- $36.8K
POLYMARKETCounter-Strike: The Huns Esports vs DEPO (BO3) - IEM Beijing: Asian Qualifier Playoffs
- O/U 2.5 Games-0.5pt45%
- Match Winner-2.0pt41%
- 2-1.5pt40%
+1 more outcomes
POLYMARKETXi Jinping out before 2027?
- No-0.2pt95%
- Yes+0.2pt5%
- Total Vol
- $12.9M
- 24h Vol
- $24.7K
POLYMARKETWill China invade Taiwan by end of 2026?
- No+0.1pt96%
- Yes-0.1pt4%
- Total Vol
- $40.5M
- 24h Vol
- $21.8K
POLYMARKETWho will be removed from Chinese Military Companies list by June 30, 2027?
- Alibaba18%
- Hesai18%
- DJI17%
+7 more outcomes
- Total Vol
POLYMARKETCounter-Strike: DENDELE CS vs EYEBALLERS (BO3) - IEM Beijing: Global Qualifier Playoffs
- Match Winner+8.5pt61%
- 2 Winner+4.0pt56%
- 1 Winner+6.0pt54%
+6 more outcomes
- Will a Chinese company have a top ___ AI model by December 31?
- Highest temperature in Beijing on September 2?
- Will Xi Jinping visit US by which date?
- Will China invade Taiwan by September 30, 2026?
- Counter-Strike: Nuclear TigeRES vs GamerLegion (BO3) - IEM Beijing: Global Qualifier Playoffs
- Top Chinese AI Company week of September 7th
- Counter-Strike: Color vs B8 (BO3) - IEM Beijing: Global Qualifier Playoffs
- Nothing Ever Happens: 2026
- Will China invade Taiwan by December 31, 2027?
- Counter-Strike: magic vs K27 (BO3) - IEM Beijing: Global Qualifier Playoffs
Frequently asked questions
- What are the current odds for FDA decision: Ivonescimab by Summit Therapeutics (in 2026)?
- Kalshi prices Yes at 93% as of September 1, 2026.
- When does FDA decision: Ivonescimab by Summit Therapeutics (in 2026) resolve?
- FDA decision: Ivonescimab by Summit Therapeutics (in 2026) is scheduled to resolve on January 1, 2027.
- How is FDA decision: Ivonescimab by Summit Therapeutics (in 2026) settled?
- Kalshi settles this market as follows: If the FDA's decision on Ivonescimab by Summit Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.